JP2020511454A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511454A5
JP2020511454A5 JP2019549411A JP2019549411A JP2020511454A5 JP 2020511454 A5 JP2020511454 A5 JP 2020511454A5 JP 2019549411 A JP2019549411 A JP 2019549411A JP 2019549411 A JP2019549411 A JP 2019549411A JP 2020511454 A5 JP2020511454 A5 JP 2020511454A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019549411A
Other languages
English (en)
Japanese (ja)
Other versions
JP7142022B2 (ja
JP2020511454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021481 external-priority patent/WO2018165385A1/en
Publication of JP2020511454A publication Critical patent/JP2020511454A/ja
Publication of JP2020511454A5 publication Critical patent/JP2020511454A5/ja
Application granted granted Critical
Publication of JP7142022B2 publication Critical patent/JP7142022B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019549411A 2017-03-08 2018-03-08 Ｍａｌｔ１の阻害剤およびそれらの使用 Active JP7142022B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762468758P 2017-03-08 2017-03-08
US62/468,758 2017-03-08
US201762553336P 2017-09-01 2017-09-01
US62/553,336 2017-09-01
PCT/US2018/021481 WO2018165385A1 (en) 2017-03-08 2018-03-08 Inhibitors of malt1 and uses thereof

Publications (3)

Publication Number Publication Date
JP2020511454A JP2020511454A (ja) 2020-04-16
JP2020511454A5 true JP2020511454A5 (enExample) 2021-04-15
JP7142022B2 JP7142022B2 (ja) 2022-09-26

Family

ID=63448912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549411A Active JP7142022B2 (ja) 2017-03-08 2018-03-08 Ｍａｌｔ１の阻害剤およびそれらの使用

Country Status (4)

Country Link
US (1) US11248007B2 (enExample)
EP (1) EP3592731A4 (enExample)
JP (1) JP7142022B2 (enExample)
WO (1) WO2018165385A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001824A2 (pt) * 2016-07-29 2019-05-07 Lupin Limited compostos de tiazol-piridina substituídos como inibidores de malt1
KR20190033607A (ko) * 2016-07-29 2019-03-29 루핀 리미티드 Malt1 저해제로서의 치환 티아졸로-피리딘 화합물
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR102359143B1 (ko) * 2018-11-28 2022-02-08 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
US20200292543A1 (en) * 2019-03-12 2020-09-17 Quidel Corporation Compositions, kits, and methods for detecting autoantibodies
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
US20230192685A1 (en) * 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US20230414629A1 (en) * 2020-11-12 2023-12-28 Monopteros Therapeutics, Inc. Materials and methods of treating cancer
AU2022425324A1 (en) 2021-12-30 2024-05-30 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tricyclic derivative inhibitor, preparation method therefor, and application thereof
EP4680232A2 (en) * 2023-03-17 2026-01-21 The Trustees of The University of Pennsylvania Combinations of retinaldehyde dehydrogenase 1 (raldh1) inhibitors and immunostimulators and methods using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
GB2504550A (en) 2012-08-03 2014-02-05 Nanyang Polytechnic Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells
EP2916656B1 (en) 2012-11-09 2017-10-25 Cornell University Small molecule inhibitors of malt1
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
KR20170007311A (ko) * 2014-05-28 2017-01-18 노파르티스 아게 신규 피라졸로 피리미딘 유도체 및 malt1 억제제로서의 그의 용도
KR20190033607A (ko) 2016-07-29 2019-03-29 루핀 리미티드 Malt1 저해제로서의 치환 티아졸로-피리딘 화합물
WO2018085247A1 (en) 2016-11-01 2018-05-11 Cornell University Compounds for malt1 degradation

Similar Documents

Publication Publication Date Title
JP2020511454A5 (enExample)
JP2019537599A5 (enExample)
JP6933770B2 (ja) Ｈｉｖカプシド阻害剤のコリン塩形態
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JP2021191798A (ja) Ｈｉｖカプシド阻害剤の固体形態
EP3094629B1 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
AU2015207757B2 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP2021008516A (ja) Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP2019527718A5 (enExample)
JP2018522866A5 (enExample)
JP2016531113A5 (enExample)
JP2017511360A5 (enExample)
JP2017537940A5 (enExample)
JP2009536620A5 (enExample)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2017526675A5 (enExample)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2018516238A5 (enExample)
JP2018519245A5 (enExample)
JP2018526413A5 (enExample)
JP2015503527A5 (enExample)
JP2005535586A5 (enExample)
JP2013513596A5 (enExample)
JP2017519781A5 (enExample)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения